Skip to main content

Advertisement

SpringerLink
Log in

Long non-coding RNA H19: a potential biomarker and therapeutic target in human malignant tumors

  • Review Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Long non-coding RNAs play important roles in cellular functions and disease development. H19, as a long non-coding RNA, is pervasively over-expressed in almost all kinds of human malignant tumors. Although many studies have reported that H19 is closely associated with tumor cell proliferation, apoptosis, invasion, metastasis, and chemoresistance, the role and mechanism of H19 in gene regulation and tumor development are largely unclear. In this review, we summarized the recent progress in the study of the major functions and mechanisms of H19 lncRNA in cancer development and progression. H19 possesses both oncogenic and tumor-suppressing activities, presumably through regulating target gene transcription, mRNA stability and splicing, and competitive inhibition of endogenous RNA degradation. Studies indicate that H19 may involve in cell proliferation and apoptosis, tumor initiation, migration, invasion, metastasis and chemoresistance and may serve as a potential biomarker for early diagnosis, prognosis, and novel molecular target for cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Consortium IHGS. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931–45.

    Article  Google Scholar 

  2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.

    Article  CAS  PubMed  Google Scholar 

  3. Gutschner T, Richtig G, Haemmerle M, Pichler M. From biomarkers to therapeutic targets-the promises and perils of long non-coding RNAs in cancer. Cancer Metastasis Rev. 2018;37(1):83–105.

    Article  CAS  PubMed  Google Scholar 

  4. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145–66.

    Article  CAS  PubMed  Google Scholar 

  5. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19(3):143–57.

    Article  CAS  PubMed  Google Scholar 

  6. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Fatima R, Akhade VS, Pal D, Rao SM. Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ther. 2015;3:5.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Thorvaldsen JL, Duran KL, Bartolomei MS. Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev. 1998;12(23):3693–702.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Jing W, Zhu M, Zhang XW, Pan ZY, Gao SS, Zhou H, et al. The significance of long noncoding RNA H19 in predicting progression and metastasis of cancers: a meta-analysis. Biomed Res Int. 2016;2016:5902678.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Chen T, Yang P, He ZY. Long non-coding RNA H19 can predict a poor prognosis and lymph node metastasis: a meta-analysis in human cancer. Minerva Med. 2016;107(4):251–8.

    PubMed  Google Scholar 

  11. Lin Y, Xu L, Wei W, Zhang X, Ying R. Long noncoding RNA H19 in digestive system cancers: a meta-analysis of its association with pathological features. Biomed Res Int. 2016;2016:4863609.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Pachnis V, Belayew A, Tilghman SM. Locus unlinked to alpha-fetoprotein under the control of the murine raf and Rif genes. Proc Natl Acad Sci USA. 1984;81(17):5523–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bartolomei MS, Zemel S, Tilghman SM. Parental imprinting of the mouse H19 gene. Nature. 1991;351(6322):153–5.

    Article  CAS  PubMed  Google Scholar 

  14. Schoenfelder S, Smits G, Fraser P, Reik W, Paro R. Non-coding transcripts in the H19 imprinting control region mediate gene silencing in transgenic Drosophila. EMBO Rep. 2007;8(11):1068–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Buiting K, Gross S, Lich C, Gillessen-Kaesbach G, el-Maarri O, Horsthemke B. Epimutations in Prader-Willi and Angelman syndromes: a molecular study of 136 patients with an imprinting defect. Am J Hum Genet. 2003;72(3):571–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Soejima H, Higashimoto K. Epigenetic and genetic alterations of the imprinting disorder Beckwith-Wiedemann syndrome and related disorders. J Hum Genet. 2013;58(7):402–9.

    Article  CAS  PubMed  Google Scholar 

  17. Wu ZR, Yan L, Liu YT, Cao L, Guo YH, Zhang Y, et al. Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours. Nat Commun. 2018;9(1):4624.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Zhang A, Shang W, Nie Q, Li T, Li S. Long non-coding RNA H19 suppresses retinoblastoma progression via counteracting miR-17-92 cluster. J Cell Biochem. 2018;119(4):3497–509.

    Article  CAS  PubMed  Google Scholar 

  19. Lv M, Zhong Z, Huang M, Tian Q, Jiang R, Chen J. lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA. Biochim Biophys Acta Mol Cell Res. 2017;1864(10):1887–99.

    Article  CAS  PubMed  Google Scholar 

  20. Zhu Z, Xu L, Wan Y, Zhou J, Fu D, Chao H, et al. Inhibition of E-cadherin expression by lnc-RNA H19 to facilitate bladder cancer metastasis. Cancer Biomark Sect A Dis Markers. 2018;22(2):275–81.

    CAS  Google Scholar 

  21. Gan L, Lv L, Liao S. Long non-coding RNA H19 regulates cell growth and metastasis via the miR-22-3p/Snail1 axis in gastric cancer. Int J Oncol. 2019;54(6):2157–68.

    CAS  PubMed  Google Scholar 

  22. Sun L, Li J, Yan W, Yao Z, Wang R, Zhou X, et al. H19 promotes aerobic glycolysis, proliferation, and immune escape of gastric cancer cells through the microRNA-519d-3p/lactate dehydrogenase A axis. Cancer Sci. 2021;112(6):2245–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Collette J, Le Bourhis X, Adriaenssens E. Regulation of human breast cancer by the long non-coding RNA H19. Int J Mol Sci. 2017;18(11):2319.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Peng F, Li TT, Wang KL, Xiao GQ, Wang JH, Zhao HD, et al. H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis. 2017;8(1):e2569.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Si H, Chen P, Li H, Wang X. Long non-coding RNA H19 regulates cell growth and metastasis via miR-138 in breast cancer. Am J Transl Res. 2019;11(5):3213–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Peperstraete E, Lecerf C, Collette J, Vennin C, Raby L, Völkel P, et al. Enhancement of breast cancer cell aggressiveness by lncRNA H19 and its Mir-675 derivative: insight into shared and different actions. Cancers. 2020;12(7):1730.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Tan D, Wu Y, Hu L, He P, Xiong G, Bai Y, et al. Long noncoding RNA H19 is up-regulated in esophageal squamous cell carcinoma and promotes cell proliferation and metastasis. Dis Esophagus. 2017;30(1):1–9.

    PubMed  Google Scholar 

  28. Li X, Yang H, Wang J, Li X, Fan Z, Zhao J, et al. High level of lncRNA H19 expression is associated with shorter survival in esophageal squamous cell cancer patients. Pathol Res Pract. 2019;215(11):152638.

    Article  CAS  PubMed  Google Scholar 

  29. Luo W, Liu W, Yao J, Zhu W, Zhang H, Sheng Q, et al. Downregulation of H19 decreases the radioresistance in esophageal squamous cell carcinoma cells. Onco Targets Ther. 2019;12:4779–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8(14):3932–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ding D, Li C, Zhao T, Li D, Yang L, Zhang B. LncRNA H19/miR-29b-3p/PGRN axis promoted epithelial-mesenchymal transition of colorectal cancer cells by acting on Wnt signaling. Mol Cells. 2018;41(5):423–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Wu KF, Liang WC, Feng L, Pang JX, Waye MM, Zhang JF, et al. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/β-catenin pathway. Exp Cell Res. 2017;350(2):312–7.

    Article  CAS  PubMed  Google Scholar 

  33. Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang R, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018;9(12):1149.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Zhang Y, Huang W, Yuan Y, Li J, Wu J, Yu J, et al. Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1. J Exp Clin Cancer Res. 2020;39(1):141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Zheng ZG, Xu H, Suo SS, Xu XL, Ni MW, Gu LH, et al. The essential role of H19 contributing to cisplatin resistance by regulating glutathione metabolism in high-grade serous ovarian cancer. Sci Rep. 2016;6:26093.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Tian X, Zuo X, Hou M, Li C, Teng Y. LncRNA-H19 regulates chemoresistance to carboplatin in epithelial ovarian cancer through microRNA-29b-3p and STAT3. J Cancer. 2021;12(19):5712–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zeng Y, Li TL, Zhang HB, Deng JL, Zhang R, Sun H, et al. Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer. Pharmacogenomics. 2019;20(3):179–88.

    Article  CAS  PubMed  Google Scholar 

  38. Zhang HB, Zeng Y, Li TL, Wang G. Correlation between polymorphisms in IGF2/H19 gene locus and epithelial ovarian cancer risk in Chinese population. Genomics. 2020;112(3):2510–5.

    Article  CAS  PubMed  Google Scholar 

  39. Iempridee T. Long non-coding RNA H19 enhances cell proliferation and anchorage-independent growth of cervical cancer cell lines. Exp Biol Med (Maywood). 2017;242(2):184–93.

    Article  CAS  PubMed  Google Scholar 

  40. Huang MC, Chou YH, Shen HP, Ng SC, Lee YC, Sun YH, et al. The clinicopathological characteristic associations of long non-coding RNA gene H19 polymorphisms with uterine cervical cancer. J Cancer. 2019;10(25):6191–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Cáceres-Durán M, Ribeiro-Dos-Santos Â, Vidal AF. Roles and mechanisms of the long noncoding RNAs in cervical cancer. Int J Mol Sci. 2020;21(24):9742.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Huang Z, Lei W, Hu HB, Zhang H, Zhu Y. H19 promotes non-small-cell lung cancer (NSCLC) development through STAT3 signaling via sponging miR-17. J Cell Physiol. 2018;233(10):6768–76.

    Article  CAS  PubMed  Google Scholar 

  43. Zhou Y, Sheng B, Xia Q, Guan X, Zhang Y. Association of long non-coding RNA H19 and microRNA-21 expression with the biological features and prognosis of non-small cell lung cancer. Cancer Gene Ther. 2017;24(8):317–24.

    Article  CAS  PubMed  Google Scholar 

  44. Zhou Y, Zhang Y. Inhibition of LncRNAH19 has the effect of anti-tumour and enhancing sensitivity to Gefitinib and Chemotherapy in Non-small-cell lung cancer in vivo. J Cell Mol Med. 2020;24(10):5811–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Zhao X, Jin X, Zhang Q, Liu R, Luo H, Yang Z, et al. Silencing of the lncRNA H19 enhances sensitivity to X-ray and carbon-ions through the miR-130a-3p /WNK3 signaling axis in NSCLC cells. Cancer Cell Int. 2021;21(1):644.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Zhang Y, Zhu R, Wang J, Cui Z, Wang Y, Zhao Y. Upregulation of lncRNA H19 promotes nasopharyngeal carcinoma proliferation and metastasis in let-7 dependent manner. Artif Cells Nanomed Biotechnol. 2019;47(1):3854–61.

    Article  CAS  PubMed  Google Scholar 

  47. Chen L, Wang Y, He J, Zhang C, Chen J, Shi D. Long noncoding RNA H19 promotes proliferation and invasion in human glioma cells by downregulating miR-152. Oncol Res. 2018;26(9):1419–28.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Chen X, Li Y, Zuo C, Zhang K, Lei X, Wang J, et al. Long non-coding RNA H19 regulates glioma cell growth and metastasis via miR-200a-mediated CDK6 and ZEB1 expression. Front Oncol. 2021;11:757650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Deng Y, Zhou L, Yao J, Liu Y, Zheng Y, Yang S, et al. Associations of lncRNA H19 polymorphisms at MicroRNA binding sites with glioma susceptibility and prognosis. Mol Ther Nucleic Acids. 2020;20:86–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Zhou Q, Liu ZZ, Wu H, Kuang WL. LncRNA H19 promotes cell proliferation, migration, and angiogenesis of glioma by regulating Wnt5a/β-catenin pathway via targeting miR-342. Cell Mol Neurobiol. 2022;42(4):1065–77.

    Article  CAS  PubMed  Google Scholar 

  51. Momtazmanesh S, Rezaei N. Long non-coding RNAs in diagnosis, treatment, prognosis, and progression of glioma: a state-of-the-art review. Front Oncol. 2021;11:712786.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Roig-Carles D, Jackson H, Loveson KF, Mackay A, Mather RL, Waters E, et al. The long non-coding RNA H19 drives the proliferation of diffuse intrinsic pontine glioma with H3K27 mutation. Int J Mol Sci. 2021;22(17):9165.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Yoshimura H, Matsuda Y, Yamamoto M, Michishita M, Takahashi K, Sasaki N, et al. Reduced expression of the H19 long non-coding RNA inhibits pancreatic cancer metastasis. Lab Invest. 2018;98(6):814–24.

    Article  CAS  PubMed  Google Scholar 

  54. Sun Y, Zhu Q, Yang W, Shan Y, Yu Z, Zhang Q, et al. LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer. J Cell Biochem. 2019;120(3):3874–86.

    Article  CAS  PubMed  Google Scholar 

  55. Wang J, Zhao L, Shang K, Liu F, Che J, Li H, et al. Long non-coding RNA H19, a novel therapeutic target for pancreatic cancer. Mol Med. 2020;26(1):30.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Sasaki N, Hirano K, Shichi Y, Gomi F, Yoshimura H, Matsushita A, et al. Gp130-Mediated STAT3 activation contributes to the aggressiveness of pancreatic cancer through H19 long non-coding RNA expression. Cancers. 2022;14(9):2055.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Wang F, Rong L, Zhang Z, Li M, Ma L, Ma Y, et al. LncRNA H19-Derived miR-675-3p promotes epithelial-mesenchymal transition and stemness in human pancreatic cancer cells by targeting the STAT3 pathway. J Cancer. 2020;11(16):4771–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Liu L, Yang J, Zhu X, Li D, Lv Z, Zhang X. Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. Febs J. 2016;283(12):2326–39.

    Article  CAS  PubMed  Google Scholar 

  59. Li M, Chai HF, Peng F, Meng YT, Zhang LZ, Zhang L, et al. Estrogen receptor β upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma. Cell Death Dis. 2018;9(11):1120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Das PK, Asha SY, Abe I, Islam F, Lam AK. Roles of non-coding RNAs on anaplastic thyroid carcinomas. Cancers. 2020;12(11):3159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Liu S, Qiu J, Tang X, Cui H, Zhang Q, Yang Q. LncRNA-H19 regulates cell proliferation and invasion of ectopic endometrium by targeting ITGB3 via modulating miR-124-3p. Exp Cell Res. 2019;381(2):215–22.

    Article  CAS  PubMed  Google Scholar 

  62. Zhang L, Wang DL, Yu P. LncRNA H19 regulates the expression of its target gene HOXA10 in endometrial carcinoma through competing with miR-612. Eur Rev Med Pharmacol Sci. 2018;22(15):4820–7.

    CAS  PubMed  Google Scholar 

  63. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, et al. The H19 non-coding RNA is essential for human tumor growth. PLoS ONE. 2007;2(9):e845.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Berteaux N, Lottin S, Monté D, Pinte S, Quatannens B, Coll J, et al. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem. 2005;280(33):29625–36.

    Article  CAS  PubMed  Google Scholar 

  65. Lv J, Yu YQ, Li SQ, Luo L, Wang Q. Aflatoxin B1 promotes cell growth and invasion in hepatocellular carcinoma HepG2 cells through H19 and E2F1. Asian Pac J Cancer Prev. 2014;15(6):2565–70.

    Article  PubMed  Google Scholar 

  66. Zhang E, Li W, Yin D, De W, Zhu L, Sun S, et al. c-Myc-regulated long non-coding RNA H19 indicates a poor prognosis and affects cell proliferation in non-small-cell lung cancer. Tumour Biol J Int Soc Oncodev Biol Med. 2016;37(3):4007–15.

    Article  CAS  Google Scholar 

  67. Long L, Spear BT. FoxA proteins regulate H19 endoderm enhancer E1 and exhibit developmental changes in enhancer binding in vivo. Mol Cell Biol. 2004;24(21):9601–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Varrault A, Gueydan C, Delalbre A, Bellmann A, Houssami S, Aknin C, et al. Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev Cell. 2006;11(5):711–22.

    Article  CAS  PubMed  Google Scholar 

  69. Li S, Yu Z, Chen SS, Li F, Lei CY, Chen XX, et al. The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. Urol Oncol. 2015;33(10):427.e421-410.

    Article  Google Scholar 

  70. Drewell RA, Goddard CJ, Thomas JO, Surani MA. Methylation-dependent silencing at the H19 imprinting control region by MeCP2. Nucleic Acids Res. 2002;30(5):1139–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Yang JJ, Liu LP, Tao H, Hu W, Shi P, Deng ZY, et al. MeCP2 silencing of LncRNA H19 controls hepatic stellate cell proliferation by targeting IGF1R. Toxicology. 2016;359–360:39–46.

    Article  PubMed  Google Scholar 

  72. Yu A, Zhao L, Kang Q, Li J, Chen K, Fu H. Transcription factor HIF1α promotes proliferation, migration, and invasion of cholangiocarcinoma via long noncoding RNA H19/microRNA-612/Bcl-2 axis. Transl Res. 2020;224:26–39.

    Article  CAS  PubMed  Google Scholar 

  73. Sun H, Wang G, Peng Y, Zeng Y, Zhu QN, Li TL, et al. H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells. Oncol Rep. 2015;33(6):3045–52.

    Article  CAS  PubMed  Google Scholar 

  74. Basak P, Chatterjee S, Weger S, Bruce MC, Murphy LC, Raouf A. Estrogen regulates luminal progenitor cell differentiation through H19 gene expression. Endocr Relat Cancer. 2015;22(4):505–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Vennin C, Spruyt N, Robin YM, Chassat T, Le Bourhis X, Adriaenssens E. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications. Cancer Lett. 2017;385:198–206.

    Article  CAS  PubMed  Google Scholar 

  76. Chen B, Yu M, Chang Q, Lu Y, Thakur C, Ma D, et al. Mdig de-represses H19 large intergenic non-coding RNA (lincRNA) by down-regulating H3K9me3 and heterochromatin. Oncotarget. 2013;4(9):1427–37.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Medrzycki M, Zhang Y, Zhang W, Cao K, Pan C, Lailler N, et al. Histone h1.3 suppresses h19 noncoding RNA expression and cell growth of ovarian cancer cells. Cancer Res. 2014;74(22):6463–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Liu C, Chen Z, Fang J, Xu A, Zhang W, Wang Z. H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation. Tumour Biol J Int Soc Oncodev Biol Med. 2016;37(1):263–70.

    Article  CAS  Google Scholar 

  79. Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng R, et al. lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. Febs J. 2014;281(16):3766–75.

    Article  CAS  PubMed  Google Scholar 

  80. Shi Y, Wang Y, Luan W, Wang P, Tao T, Zhang J, et al. Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. PLoS ONE. 2014;9(1):e86295.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Harari-Steinfeld R, Gefen M, Simerzin A, Zorde-Khvalevsky E, Rivkin M, Ella E, et al. The lncRNA H19-Derived MicroRNA-675 promotes liver necroptosis by targeting FADD. Cancers. 2021;13(3):411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Yang J, Shi X, Yang M, Luo J, Gao Q, Wang X, et al. Glycolysis reprogramming in cancer-associated fibroblasts promotes the growth of oral cancer through the lncRNA H19/miR-675-5p/PFKFB3 signaling pathway. Int J Oral Sci. 2021;13(1):12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Xu H, Mei Q, Xiong C, Zhao J. Tumor-suppressing effects of miR-141 in human osteosarcoma. Cell Biochem Biophys. 2014;69(2):319–25.

    Article  CAS  PubMed  Google Scholar 

  84. He P, Zhang Z, Huang G, Wang H, Xu D, Liao W, et al. miR-141 modulates osteoblastic cell proliferation by regulating the target gene of lncRNA H19 and lncRNA H19-derived miR-675. Am J Transl Res. 2016;8(4):1780–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Zhu Y, Ni T, Lin J, Zhang C, Zheng L, Luo M. Long non-coding RNA H19, a negative regulator of microRNA-148b-3p, participates in hypoxia stress in human hepatic sinusoidal endothelial cells via NOX4 and eNOS/NO signaling. Biochimie. 2019;163:128–36.

    Article  CAS  PubMed  Google Scholar 

  86. Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y, et al. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochem Biophys Acta. 2010;1803(4):443–51.

    Article  CAS  PubMed  Google Scholar 

  87. Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J, et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. Febs J. 2012;279(17):3159–65.

    Article  CAS  PubMed  Google Scholar 

  88. Li C, Lei B, Huang S, Zheng M, Liu Z, Li Z, et al. H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma. Am J Transl Res. 2015;7(10):1747–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Zhou X, Ye F, Yin C, Zhuang Y, Yue G, Zhang G. The interaction between MiR-141 and lncRNA-H19 in regulating cell proliferation and migration in gastric cancer. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2015;36(4):1440–52.

    Article  Google Scholar 

  90. Wang SH, Wu XC, Zhang MD, Weng MZ, Zhou D, Quan ZW. Long noncoding RNA H19 contributes to gallbladder cancer cell proliferation by modulated miR-194-5p targeting AKT2. Tumour Biol J Int Soc Oncodev Biol Med. 2016;37(7):9721–30.

    Article  CAS  Google Scholar 

  91. Yang W, Ning N, Jin X. The lncRNA H19 promotes cell proliferation by competitively binding to miR-200a and derepressing β-catenin expression in colorectal cancer. Biomed Res Int. 2017;2017:2767484.

    PubMed  PubMed Central  Google Scholar 

  92. Chen L, Li Q, Jiang Z, Li C, Hu H, Wang T, et al. Chrysin induced cell apoptosis through H19/let-7a/COPB2 axis in gastric cancer cells and inhibited tumor growth. Front Oncol. 2021;11:651644.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Fellig Y, Ariel I, Ohana P, Schachter P, Sinelnikov I, Birman T, et al. H19 expression in hepatic metastases from a range of human carcinomas. J Clin Pathol. 2005;58(10):1064–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 2013;333(2):213–21.

    Article  CAS  PubMed  Google Scholar 

  95. Zhang L, Yang F, Yuan JH, Yuan SX, Zhou WP, Huo XS, et al. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis. 2013;34(3):577–86.

    Article  PubMed  Google Scholar 

  96. Li X, Lin Y, Yang X, Wu X, He X. Long noncoding RNA H19 regulates EZH2 expression by interacting with miR-630 and promotes cell invasion in nasopharyngeal carcinoma. Biochem Biophys Res Commun. 2016;473(4):913–9.

    Article  CAS  PubMed  Google Scholar 

  97. Liu G, Xiang T, Wu QF, Wang WX. Long noncoding RNA H19-Derived miR-675 enhances proliferation and invasion via RUNX1 in gastric cancer cells. Oncol Res. 2016;23(3):99–107.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015;6(26):22513–25.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Nagel ZD, Kitange GJ, Gupta SK, Joughin BA, Chaim IA, Mazzucato P, et al. DNA repair capacity in multiple pathways predicts chemoresistance in glioblastoma multiforme. Can Res. 2017;77(1):198–206.

    Article  CAS  Google Scholar 

  100. Wu YH, Huang YF, Chang TH, Chou CY. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression. Int J Cancer. 2017;141(11):2305–17.

    Article  CAS  PubMed  Google Scholar 

  101. Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene. 2007;26(33):4877–81.

    Article  CAS  PubMed  Google Scholar 

  102. Si X, Zang R, Zhang E, Liu Y, Shi X, Zhang E, et al. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget. 2016;7(49):81452–62.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Wang X, Pei X, Guo G, Qian X, Dou D, Zhang Z, et al. Exosome-mediated transfer of long noncoding RNA H19 induces doxorubicin resistance in breast cancer. J Cell Physiol. 2020;235(10):6896–904.

    Article  CAS  PubMed  Google Scholar 

  104. Wang J, Xie S, Yang J, Xiong H, Jia Y, Zhou Y, et al. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J Hematol Oncol. 2019;12(1):81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Jiang P, Wang P, Sun X, Yuan Z, Zhan R, Ma X, et al. Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy. OncoTargets Ther. 2016;9:3501–9.

    CAS  Google Scholar 

  106. Pan Y, Zhang Y, Liu W, Huang Y, Shen X, Jing R, et al. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Cell Death Dis. 2019;10(2):106.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Zhang EB, Han L, Yin DD, Kong R, De W, Chen J. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Med Oncol. 2014;31(5):914.

    Article  PubMed  Google Scholar 

  108. Li H, Yu B, Li J, Su L, Yan M, Zhu Z, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5(8):2318–29.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Can Res. 2006;66(10):5330–7.

    Article  CAS  Google Scholar 

  110. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis. 2010;31(3):350–8.

    Article  CAS  PubMed  Google Scholar 

  111. Wang SH, Wu XC, Zhang MD, Weng MZ, Zhou D, Quan ZW. Upregulation of H19 indicates a poor prognosis in gallbladder carcinoma and promotes epithelial-mesenchymal transition. Am J Cancer Res. 2016;6(1):15–26.

    CAS  PubMed  Google Scholar 

  112. Zhao H, Peng R, Liu Q, Liu D, Du P, Yuan J, et al. The lncRNA H19 interacts with miR-140 to modulate glioma growth by targeting iASPP. Arch Biochem Biophys. 2016;610:1–7.

    Article  CAS  PubMed  Google Scholar 

  113. Jiang X, Yan Y, Hu M, Chen X, Wang Y, Dai Y, et al. Increased level of H19 long noncoding RNA promotes invasion, angiogenesis, and stemness of glioblastoma cells. J Neurosurg. 2016;124(1):129–36.

    Article  CAS  PubMed  Google Scholar 

  114. Jia P, Cai H, Liu X, Chen J, Ma J, Wang P, et al. Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a. Cancer Lett. 2016;381(2):359–69.

    Article  CAS  PubMed  Google Scholar 

  115. Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z, et al. H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35(9):9163–9.

    Article  CAS  Google Scholar 

  116. Ma L, Tian X, Wang F, Zhang Z, Du C, Xie X, et al. The long noncoding RNA H19 promotes cell proliferation via E2F–1 in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2016;17(10):1051–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Verhaegh GW, Verkleij L, Vermeulen SH, den Heijer M, Witjes JA, Kiemeney LA. Polymorphisms in the H19 gene and the risk of bladder cancer. Eur Urol. 2008;54(5):1118–26.

    Article  CAS  PubMed  Google Scholar 

  118. Hua Q, Lv X, Gu X, Chen Y, Chu H, Du M, et al. Genetic variants in lncRNA H19 are associated with the risk of bladder cancer in a Chinese population. Mutagenesis. 2016;31(5):531–8.

    Article  CAS  PubMed  Google Scholar 

  119. Yang C, Tang R, Ma X, Wang Y, Luo D, Xu Z, et al. Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the Chinese Han population. Oncotarget. 2015;6(17):15311–20.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Yin Z, Cui Z, Li H, Li J, Zhou B. Polymorphisms in the H19 gene and the risk of lung Cancer among female never smokers in Shenyang, China. BMC Cancer. 2018;18(1):893.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Li S, Hua Y, Jin J, Wang H, Du M, Zhu L, et al. Association of genetic variants in lncRNA H19 with risk of colorectal cancer in a Chinese population. Oncotarget. 2016;7(18):25470–7.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Qin W, Wang X, Wang Y, Li Y, Chen Q, Hu X, et al. Functional polymorphisms of the lncRNA H19 promoter region contribute to the cancer risk and clinical outcomes in advanced colorectal cancer. Cancer Cell Int. 2019;19:215.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Cui P, Zhao Y, Chu X, He N, Zheng H, Han J, et al. SNP rs2071095 in LincRNA H19 is associated with breast cancer risk. Breast Cancer Res Treat. 2018;171(1):161–71.

    Article  CAS  PubMed  Google Scholar 

  124. Tan T, Li J, Wen Y, Zou Y, Yang J, Pan J, et al. Association between lncRNA-H19 polymorphisms and hepatoblastoma risk in an ethic Chinese population. J Cell Mol Med. 2021;25(2):742–50.

    Article  CAS  PubMed  Google Scholar 

  125. Lu Y, Tan L, Shen N, Peng J, Wang C, Zhu Y, et al. Association of lncRNA H19 rs217727 polymorphism and cancer risk in the Chinese population: a meta-analysis. Oncotarget. 2016;7(37):59580–88.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Chu M, Yuan W, Wu S, Wang Z, Mao L, Tian T, et al. Quantitative assessment of polymorphisms in H19 lncRNA and cancer risk: a meta-analysis of 13,392 cases and 18,893 controls. Oncotarget. 2016;7(48):78631–39.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Liu X, Zhao Y, Li Y, Zhang J. Quantitative assessment of lncRNA H19 polymorphisms and cancer risk: a meta-analysis based on 48,166 subjects. Artif Cells Nanomed Biotechnol. 2020;48(1):15–27.

    Article  CAS  PubMed  Google Scholar 

  128. Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl. 2015;9(3–4):358–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Wang J, Yang K, Yuan W, Gao Z. Determination of serum exosomal H19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis. Med Sci Monit. 2018;24:9307–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Zhong G, Wang K, Li J, Xiao S, Wei W, Liu J. Determination of serum exosomal H19 as a noninvasive biomarker for breast cancer diagnosis. OncoTargets Ther. 2020;13:2563–71.

    Article  CAS  Google Scholar 

  131. Liu N, Zhou Q, Qi YH, Wang H, Yang L, Fan QY. Effects of long non-coding RNA H19 and microRNA let7a expression on thyroid cancer prognosis. Exp Mol Pathol. 2017;103(1):71–7.

    Article  CAS  PubMed  Google Scholar 

  132. Shima H, Kida K, Adachi S, Yamada A, Sugae S, Narui K, et al. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness. Breast Cancer Res Treat. 2018;170(3):507–16.

    Article  CAS  PubMed  Google Scholar 

  133. Zhang TJ, Zhou JD, Zhang W, Lin J, Ma JC, Wen XM, et al. H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia. Clin Epigenet. 2018;10:47.

    Article  Google Scholar 

  134. Xu Y, Wang Z, Jiang X, Cui Y. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition. Biomed Pharmacother. 2017;92:17–23.

    Article  CAS  PubMed  Google Scholar 

  135. Shi G, Li H, Gao F, Tan Q. lncRNA H19 predicts poor prognosis in patients with melanoma and regulates cell growth, invasion, migration and epithelial-mesenchymal transition in melanoma cells. OncoTargets Ther. 2018;11:3583–95.

    Article  Google Scholar 

  136. Jiao X, Lu J, Huang Y, Zhang J, Zhang H, Zhang K. Long non-coding RNA H19 may be a marker for prediction of prognosis in the follow-up of patients with papillary thyroid cancer. Cancer Biomark Sect A Dis Markers. 2019;26(2):203–7.

    CAS  Google Scholar 

  137. Zhong X, Huang S, Liu D, Jiang Z, Jin Q, Li C, et al. Galangin promotes cell apoptosis through suppression of H19 expression in hepatocellular carcinoma cells. Cancer Med. 2020;9(15):5546–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Li DY, Busch A, Jin H, Chernogubova E, Pelisek J, Karlsson J, et al. H19 induces abdominal aortic aneurysm development and progression. Circulation. 2018;138(15):1551–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I, et al. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J Transl Med. 2009;7:69.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Scaiewicz V, Sorin V, Fellig Y, Birman T, Mizrahi A, Galula J, et al. Use of H19 gene regulatory sequences in DNA-based therapy for pancreatic cancer. J Oncol. 2010;2010:178174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Amit D, Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J Transl Med. 2010;8:134.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Amit D, Hochberg A. Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. Int J Clin Exp Med. 2012;5(4):296–305.

    CAS  PubMed  PubMed Central  Google Scholar 

  143. Gofrit ON, Benjamin S, Halachmi S, Leibovitch I, Dotan Z, Lamm DL, et al. DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer. J Urol. 2014;191(6):1697–702.

    Article  CAS  PubMed  Google Scholar 

  144. Lavie O, Edelman D, Levy T, Fishman A, Hubert A, Segev Y, et al. A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer. Arch Gynecol Obstet. 2017;295(3):751–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by grants from Traditional Chinese Medicine Bureau of Guangdong Province (No. 20221282), National Natural Science Foundation of China (No. 82003870), and Natural Science Foundation of Changsha (No. kq2014012).

Author information

Authors and Affiliations

  1. Department of Pharmacy, Anhui No.2 Provincial People’s Hospital, Hefei, 230041, People’s Republic of China

    Rui Zhang

  2. Department of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410008, People’s Republic of China

    Ying Zeng

  3. Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, People’s Republic of China

    Jun-Li Deng

Authors
  1. Rui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun-Li Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RZ collected the literature and wrote the manuscript; YZ revised the manuscript; JLD wrote and critically revised the manuscript, prepared the figures and completed the final editing. JLD and YZ provided financial and instrumental support. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Jun-Li Deng.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, R., Zeng, Y. & Deng, JL. Long non-coding RNA H19: a potential biomarker and therapeutic target in human malignant tumors. Clin Exp Med 23, 1425–1440 (2023). https://doi.org/10.1007/s10238-022-00947-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-022-00947-5

Keywords

Search

Navigation